19 Dec Cutting Edge PCOS Research by Dr. Williams
We are excited to share with you that Dr. Williams’ research on PCOS has been published in the November – December 2019 issue of Human Reproduction Update titled “First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.”
Research on Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is the most frequent cause of anovulatory infertility. In women with PCOS, effective ovulation induction serves as an important first-line treatment for women who aren’t ovulating and are trying to conceive.
Dr. Williams and the rest of the team studied women who weren’t ovulating and aimed to evaluate the effectiveness of different ovulation induction medications such as letrozole alone and clomiphene citrate (CC), also known as Clomid, plus metformin, versus CC alone, as the first-line choice for ovulation induction in women with PCOS and infertility.
The study concluded that in women with PCOS, letrozole improves live birth and clinical pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be recommended as the preferred first-line treatment for women with PCOS and infertility. CC plus metformin may increase clinical pregnancy and may reduce time-to-pregnancy compared to CC alone, while there is insufficient evidence of a difference on live birth.
You can read the entire journal article here.
We’re excited to have RMSCVA be a part of this groundbreaking PCOS research!